Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07764133
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian CancerUniversity of Tennessee Graduate School of MedicineRecruiting
NCT07764133Recruiting
—
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation a...University of Tennessee G...
NCT07763197
Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)Natera, Inc.Recruiting
NCT07763197Recruiting
—
Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle...Natera, Inc.
NCT07762924
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryFudan UniversityRecruitingPhase 2
NCT07762924Recruiting
Phase 2
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Fol...Fudan University
NCT07762157
The Effectiveness of Tele-pulmonary Rehabilitation Program on People With Chronic Obstructive Pulmonary Disease (COPD) After Hospitalization for Acute ExacerbationNorth District HospitalRecruitingNot Applicable
NCT07762157Recruiting
Not Applicable
The Effectiveness of Tele-pulmonary Rehabilitation Program on People With Chroni...North District Hospital
NCT07762443
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia AreataJiangsu vcare pharmaceutical technology co., LTDNot Yet RecruitingPhase 1
NCT07762443Not Yet Recruiting
Phase 1
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Are...Jiangsu vcare pharmaceuti...
NCT07763938
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell MalignanciesNanjing Legend Biotech Co.Not Yet RecruitingPhase 1
NCT07763938Not Yet Recruiting
Phase 1
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relap...Nanjing Legend Biotech Co...
NCT07762638
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302Idorsia Pharmaceuticals Ltd.Unknown
NCT07762638Unknown
—
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated...Idorsia Pharmaceuticals L...
NCT07763964
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.ADIUMCompletedNot Applicable
NCT07763964Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07763587
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management RegimenFirst Teaching Hospital of Tianjin University of Traditional Chinese MedicineNot Yet RecruitingNot Applicable
NCT07763587Not Yet Recruiting
Not Applicable
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Ben...First Teaching Hospital o...
NCT07762027
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus InfectionAssembly BiosciencesNot Yet RecruitingPhase 2
NCT07762027Not Yet Recruiting
Phase 2
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Part...Assembly Biosciences
NCT07763392
Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digital Testing Platform Across the LifespanIntraneuronRecruiting
NCT07763392Recruiting
—
Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digit...Intraneuron
NCT07764055
A Trial of Absorbable Regenerated Oxidized Cellulose for Surgical Hemostasis)Medprin Regenerative Medical Technologies Co., Ltd.CompletedPhase 3
NCT07764055Completed
Phase 3
A Trial of Absorbable Regenerated Oxidized Cellulose for Surgical Hemostasis)Medprin Regenerative Medi...
NCT07763912
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fed Study.ADIUMCompletedNot Applicable
NCT07763912Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07764354
How Patient Education Helps Patients With Chronic Musculoskeletal Disorders Stick to Home Exercise for Pain Relief.Imam Abdulrahman Bin Faisal UniversityRecruitingNot Applicable
NCT07764354Recruiting
Not Applicable
How Patient Education Helps Patients With Chronic Musculoskeletal Disorders Stic...Imam Abdulrahman Bin Fais...
NCT07763990
THE EVALUATION OF THE SAFETY AND PERFORMANCE OF AN INJECTABLE HYALURONIC ACID FILLERHallura Ltd.RecruitingNot Applicable
NCT07763990Recruiting
Not Applicable
THE EVALUATION OF THE SAFETY AND PERFORMANCE OF AN INJECTABLE HYALURONIC ACID FI...Hallura Ltd.
NCT07763951
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.ADIUMCompletedNot Applicable
NCT07763951Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07762092
A Post Authorization Registry Study of Participants Treated With LEQEMBIEisai LimitedNot Yet Recruiting
NCT07762092Not Yet Recruiting
—
A Post Authorization Registry Study of Participants Treated With LEQEMBIEisai Limited
NCT07762040
Predictors of Progression Independent of Relapse Activity in Relapsing Remitting Multiple SclerosisAssiut UniversityNot Yet Recruiting
NCT07762040Not Yet Recruiting
—
Predictors of Progression Independent of Relapse Activity in Relapsing Remitting...Assiut University
NCT07763236
Indocyanine Green Fluorescence in Endoscopic Resection of Non-Functioning Pituitary AdenomasTomislav FelbabićCompletedNot Applicable
NCT07763236Completed
Not Applicable
Indocyanine Green Fluorescence in Endoscopic Resection of Non-Functioning Pituit...Tomislav Felbabić
Result Breakdown
Recruiting7 (35%)
Completed6 (30%)
Not yet recruiting6 (30%)
Unknown1 (5%)
not_applicable9 (45%)
Not Specified6 (30%)
Phase 22 (10%)
Phase 12 (10%)
Phase 31 (5%)